Data With TTFields Raise Questions Around the Future of Immunotherapy in Metastatic NSCLC
August 7th 2023
Tony S.K. Mok, MD, BMSc, FRCPC, FASCO, provides perspective on the use of tumor treating fields in lung cancer, the use of anti–PD-L1 inhibitors approved in China, and the potential impact of the microbiome on response with immunotherapy.